[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
@RheumNow Dr. John Cush
Dr. John Cush posts on X about $abbv, health, longterm, poster the most. They currently have XXXXXX followers and XX posts still getting attention that total XXX engagements in the last XX hours.
Engagements: XXX #
- X Week XXXXX -XX%
- X Month XXXXXX +23%
- X Months XXXXXXX +24%
- X Year XXXXXXX +31%
Mentions: X #
- X Month XX -XX%
- X Months XXX +17%
- X Year XXX +123%
Followers: XXXXXX #
- X Week XXXXXX +0.06%
- X Month XXXXXX +0.24%
- X Months XXXXXX +4.30%
- X Year XXXXXX +7.80%
CreatorRank: XXXXXXXXX #
Social Influence
Social category influence stocks XXXXX% currencies XXXX% finance XXXX%
Social topic influence $abbv #46, health 18.75%, longterm 6.25%, poster 6.25%, what is 6.25%, reduce 6.25%, fomo 6.25%, countdown XXXX%
Top accounts mentioned or mentioned by @rheumat_aravind
Top assets mentioned AbbVie Inc (ABBV)
Top Social Posts
Top posts by engagements in the last XX hours
"Partial vs Total Knee Replacement: Is One Superior Patients with osteoarthritis (OA) primarily affecting only one knee joint compartment did just as well with partial knee replacement (PKR) as with total arthroplasty after XX years in a randomized trial -- and maybe a little bit better"
X Link 2025-11-29T23:00Z 24.9K followers, XXX engagements
"Two years of a JAKi in GCA 📊 Dr. Dua and Dr. Boone share their thoughts on the latest data from a Phase X trial with a JAKi in GCA including key long-term efficacy and safety outcomes. Sponsored by AbbVie Medical Affairs + Health Impact"
X Link 2025-12-01T15:00Z 24.9K followers, XXX engagements
"A JAKi in GCA: 2-year efficacy and safety results in a Phase X study Discover how continued treatment with a JAKi impacted disease remission and steroid use. Sponsored by AbbVie Medical Affairs + Health Impact"
X Link 2025-12-05T18:01Z 24.9K followers, XXX engagements
"NEW ONLINE ACR POSTER: 2-year efficacy and safety outcomes with a JAKi in patients with GCA Click to see the latest results from a Phase X trial presented at ACR 2025 sponsored by AbbVie Medical Affairs + Health Impact"
X Link 2025-12-08T18:00Z 24.9K followers, XXX engagements
"RHEUM Survey What is the Sensitivity of the ANA test"
X Link 2025-12-10T16:42Z 24.9K followers, XXX engagements
"Review of neonatal Fc receptor (FcRn) blockers being developed by J&J argenx & UCB showing utility in autoimmune dz as they reduce autoantibodies. FcRn inhibitor market may be worth USD XXX billion by 2035. Approved for myasthenia gravis & being developed in Sjgrens SLE AIHA etc"
X Link 2025-11-19T21:00Z 24.9K followers, 1034 engagements
"The countdown is on Drs. Jack Cush & Artie Kavanaugh are previewing whats coming to RheumNow Live 2026 in Dallas (Feb 78) and you dont want FOMO on this one. ✅ Register now at 🔥Early bird pricing ends December XX Get the inside scoop on whats ahead and lock in your spot now"
X Link 2025-12-11T01:00Z 24.9K followers, XXX engagements